Zentalis Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US98943L1070

SecurityZNTL / Zentalis Pharmaceuticals, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership125,767 shares
Latest Disclosed Value $ 294,295
Invesco Ltd. reports 33.31% decrease in ownership of ZNTL / Zentalis Pharmaceuticals, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 125,767 shares of Zentalis Pharmaceuticals, Inc. (US:ZNTL) valued at $294,295 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 188,582 shares of Zentalis Pharmaceuticals, Inc.. This represents a change in shares of -33.31% during the quarter. The current value of the position is $460,307 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 125,767 -62,815 -33.31 294 15.75 0.0000
2026-02-19 2025-12-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 188,582 14,961 8.62 255 -3.05 0.0000
2025-11-13 2025-09-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 173,621 17,907 11.50 262 45.56 0.0000
2025-08-13 2025-06-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 155,714 6,230 4.17 181 -24.05 0.0000
2025-05-12 2025-03-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 149,484 98,612 193.84 238 53.90 0.0000
2025-02-13 2024-12-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 50,872 -590 -1.15 154 -18.52 0.0000
2024-11-12 2024-09-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 51,462 -2,347 -4.36 189 -14.09 0.0000
2024-08-13 2024-06-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 53,809 -557 -1.02 220 -74.30 0.0000
2024-05-14 2024-03-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 54,366 29,416 117.90 857 127.06 0.0002
2024-02-13 2023-12-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 24,950 -111,611 -81.73 378 -86.24 0.0001
2023-11-13 2023-09-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 136,561 6,281 4.82 2,739 -25.47 0.0007
2023-08-11 2023-06-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 130,280 104,647 408.25 3,675 735.23 0.0010
2023-05-12 2023-03-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 25,633 575 2.29 441 -12.70 0.0001
2023-02-13 2022-12-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 25,058 -1,958 -7.25 505 -13.99 0.0001
2022-11-14 2022-09-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 27,016 3,391 14.35 586 -11.75 0.0002
2022-08-15 2022-06-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 23,625 -73,830 -75.76 664 -85.23 0.0002
2022-05-16 2022-03-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 97,455 -121,660 -55.52 4,497 -75.58 0.0011
2022-02-14 2021-12-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 219,115 88,303 67.50 18,419 111.28 0.0044
2021-11-15 2021-09-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 130,812 -14,437 -9.94 8,718 12.81 0.0022
2021-08-17 2021-06-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 145,249 -87,758 -37.66 7,728 -23.56 0.0019
2021-05-17 2021-03-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 233,007 -43,062 -15.60 10,110 -29.49 0.0027
2021-02-16 2020-12-31 13F ZENTALIS PHARMACEUTICALS COM 98943L107 276,069 2,960 1.08 14,339 60.61 0.0042
2020-11-16 2020-09-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 273,109 -4,284 -1.54 8,928 -32.97 0.0030
2020-08-14 2020-06-30 13F ZENTALIS PHARMACEUTICALS COM 98943L107 277,393 277,393 13,320 0.0048
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.